Clinical Trial Update: Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, efficacy, and pharmacokinetics of rifaximin in moderate-to-severe papulopustular rosacea completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papulopustular Rosacea

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Alfasigma S.p.A. | Conditions: Papulopustular Rosacea | Phase 2 | Status: COMPLETED | Results posted: 2024-04-24